OptimizeRx appoints Mary Varghese Presti to Board, expands to seven directors

Filed April 9, 2026 · Period ending April 3, 2026 · ~1 min read

Key Changes

• medium

  Mary Varghese Presti appointed as independent director effective April 3, 2026, serving until the 2026 annual meeting. Board expanded from six to seven members to accommodate the appointment.

  Item 5.02 verify on EDGAR →
• medium

  Varghese Presti assigned to Audit Committee, which oversees financial reporting and internal controls. This strengthens the committee's oversight capabilities.

  Item 5.02 verify on EDGAR →
• low

  New director will receive standard compensation: $55,000 annual cash retainers ($45,000 base plus $10,000 for Audit Committee service) and approximately $175,000 in annual equity grants.

  Item 5.02 verify on EDGAR →